Pharming Group NV is the latest European company to enter into an equity funding agreement with YA Global of the US giving it an option to issue up to a total of €20 million in Pharming shares at any time during the next 36 months.
Active Biotech AB, a Swedish biotech company with five drug projects under clinical development, has announced details of its SEK 256 million (€23.8 million) rights issue scheduled for completion on 10 June 2009.
A spin-out from University College London (UCL) has obtained finance from GlaxoSmithKline to develop what may be the first product ever to combine a small molecule drug with an antibody in order to treat disease.
Merck Serono has announced two separate funding initiatives that will support biotechnology companies conducting research in one or more of its core therapeutic areas. The first is a new venture capital fund, and the second, a deal with a unit of the American National Multiple Sclerosis Society.
Roche said it is acquiring Innovatis AG, a German cell analysis company, for €15 million. The sellers are two private equity funds operated by Ventizz Capital Partners Advisory AG.
The ReNeuron Group Plc, which has received permission for a first-in-man trial of a neural stem cell treatment for stroke, has lined up financing for the year ahead.
The Roche Group has reached a “friendly” agreement to acquire all the outstanding shares of Genentech Inc that it doesn’t own for $95 per share or $46.8 billion in cash.
Merck & Co. is acquiring Schering Plough Corp in a combination valued at $41.1 billion.
After encountering resistance from the management of Genentech, the Roche Group has increased its hostile offer for all the shares of Genentech Inc that it doesn’t already own to $93 per share from $86.50 per share.
Pharmexa A/S of Denmark has decided to change its therapeutic focus from vaccines to human antibodies and will accomplish this by merging with the privately-owned Norwegian antibody research company, Affitech AS.